Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
DOP018: Long-term follow-up after ileorectal anastomosis in Ulcerative Colitis (UC) identified factors associated with rectal outcome: a multicenter retrospective cohort of 343 patients from the GETAID/GETAID Surgery
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 2 - Altering disease outcome in IBD (Keywords: colectomy, UC, ileorectal anastomosis)
Authors: Mathieu Uzzan
DOP019: Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords: autolous stem cell transplant, CD)
Authors: Elena Ricart
DOP019: Opportunistic infections in inflammatory bowel disease (IBD): relevance of immunosuppressive therapy and mortality
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first?
Authors: Yamile Zabana
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords:autologous stem cell transplant, clinical trials, CD)
Authors: James Lindsay
DOP020: The prevalence of autoimmune diseases in a nationwide paediatric inflammatory bowel disease cohort
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first?
Authors: Victoria Merrick
DOP021: Long term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: ten years of Milan experience without CD34+ cell selection.
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords:autologous stem cell transplant, clinical trials, CD)
Authors: Andrea Cassinotti
DOP022: Incidence of and risk factors for thromboembolism in Inflammatory Bowel Disease: results from a population-based inception cohort
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first? (Keywords: disease activity, IBD, thromboembolic events)
Authors: Zuzana Vegh
DOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel Disease
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords: IBD)
Authors: Peter Higgins
DOP023: Evaluation of global coagulation profiles in patients with acute severe colitis: Implications for thromboprophylaxis
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first? (Keywords: complications, IBD, UC, thromboembolic events)
Authors: Ben Griffiths
DOP023: Safety and efficacy of a novel i.v. targeted pegylated liposomal prednisolone (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords: IBD, UC, trials)
Authors: Séverine Vermeire
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords: IBD, CD, vagus nerve-vagus nerve simulation)
Authors: Bruno Bonaz
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD
Authors: Barrett Levesque
DOP025: Description of colorectal cancers detected in the Dutch population based IBD-SL cohort
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first? (Keywords: adenocarcinoma, cancer, cancer in ibd, colorectal cancer surveillance, disease outcome, endoscopic asessment, IBD, CD, UC, monitoring, surveillance)
Authors: Tim van den Heuvel
DOP026: Increased cancer risk in Dutch Crohns disease patients: results from the population based IBD-SL cohort
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first? (Keywords: adenocarcinoma, anti-TNF, biologic treatment, cancer, cancer in ibd, colorectal cancer surveillance, disease outcome, IBD, CD, UC, immunosuppressive agents, infliximab, lymphoma, monitoring, mortality)
Authors: Tim van den Jeuvel
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 3 - Novel therapies in IBD (Keywords: adalimumab, anti-TNF, AZA, IBD, CD, UC, immunosuppressive agents, infliximab, mucosal immunology)
Authors: Manon Wildenberg
DOP027: Survival in inflammatory bowel disease related colorectal cancer
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 3 – Safety first? (Keywords: cancer in ibd, mortality)
Authors: Alan Askari
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: anti-TNF, biologic treatment, disease outcome, infliximab)
Authors: Krisztina Gecse
DOP029: Outcomes of a managed switching program changing IBD patients established on originator infliximab to biosimilar infliximab
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: anti-TNF, biologic treatment, IBD)
Authors: Fraser Cummings
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: IBD, infliximab, biosimilars, switch)
Authors: Lisa Smits
DOP030: GLPG0974, an FFA2 antagonist, in ulcerative colitis: efficacy and safety in a multicenter proof-of-concept study
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD
Authors: Séverine Vermeire